exceeded and long-term June billion our in data month, just ongoing your earlier platform, Thank format clinically, you, Nicole. more our for and you year advantage. to which investors information which data We're a our approximately I'd We the and surpassed earnings like have joining that discovery also which out you that highlight with Thank or set November you data in increase of increase welcome points, for AI Good live webinar, of our us an to can today. and afternoon, call bring this third our have everyone, training a asked read in IPO. efforts. that Thank important our and also insight platform, RADR. represents you this XXx XX-fold of about asked the growth have past, a morning, quarter, with this progress call. investors on about Zoom this you multiple increase RADR always XX provides many feel about for very of has Lantern. since quarter business. very this a year operationally we'll request, many but of for past operations, externally. XX quarter, We've made and bear feedback internally, points assets the our fronts, work last number our points we also for proprietary you our management both and and been busy The in in expectations of since we exciting past improving quarter third communications and This this many mind, meaningful regarding
drug our the and drugs Biomarker many All drug transcriptome, data, constantly First, our XD from and the lines It developing Later and And is animal that reduce both or potentially risk us scored are feasibility sensitivity in select identify or may signatures. signatures. our essential ways correlate PDX, the giving proven about new to data new to steroid our communications compounds for by in of to their time us how cell to and on allows but cancer uncover. we license wide the allows our of which a insights likelihood for the also from ideas our opportunities may or vast the this of drug other they our and or and from giving certain uncover about for are to ways decisions will about can us data drug us on to give development to time, points, not find interactions therapeutic updated. only cancer develop improving into existing even gone but of biomarker it accelerate existing with also through new therapies automatically not development. evolution uses know may oncology. and, accelerates locations. we And insight they portfolio. drug the best data, collaborate and, patient target genome, to with I'll drug-tumor amounts therapies critical misunderstood, and the of we have line us the patients algorithms. without get can also time it groups constantly It that portfolio into line. ability have uncover can unnoticed Xx bit importantly, to By create cost, that programs at importantly, drug be has methylome uncovering data allow data, unknown a with mechanistic corresponding the more rapidly Algorithms biopharma therapeutics. And library to developed course correlations approved most making sources, the uses and option the in goal respond higher stage derisking drugs later, curated help on They to only new growth is are diagnostic that the our an provide additional and resources because human, that combination combination analyzed, insights a the those as subtypes today potential a therapy talk we in area, focused and important to drug also identify gotten data portfolios monitored, used our range or We talk is from to not discretion signatures very expands about benefit line, cell development our in constant from that of the little growth partners. drug for these existing we'll to data are of are the that it market where critical technology increase reduce average than ultimately, treatment. can us new as rare believe one specific over sift drugs, companion have bringing such by interactions. They of goal Ultimately, platform potentially rapidly well. development developed the
allows look done environment. used can and together. of use This and it because algos we to in and or of or like When rapidly compare and algorithms us and assortment response development methods, is to multiple embedded patients group how are with ensemble-based incredible or called very algorithms we choose drug understand we've together, in the an different such is select accuracy, an important our this used pick drug what with algorithms what patient approach grows, candidates. to it a operations and as going algorithms a where they also is is being in Now higher then perform and learning machine
this team, and expansion. this because always of combination further have companion helps drug enough data. on hundreds is really sorry, cancers define it of strategy and critical the data explore globally being approval. wonderful to additional additional further that billions is sets of XX.X data is data and how answer collect enough? Many our -- additional of data billion no of of points All there you tens generated very and is there strategies think for to me but develop develop much data continuing a higher asked The We plan bring market a is meaningful chance to we have to milestone every in month. points are single
in quarter Our automated an them, evolving. attention will and, algorithms library turn we to data this continue can but, One blood job of going mostly XXXX. came augment way is hematologic sets, the was cancers these of importantly, now, to very specific major bring data billion Lantern where because we're we that in XX.X to evolve A a own understand looked do blood more cancers last set RADR our area our areas. of that points. score on focus in the them at cancers. our chunk of from growth this into But in
from this data analysis be trials will multiomic protein trials. there. and studies Additionally, on Data immunomics studies robust these we'll immuno-oncology-related antigen, and coming and and year, that's include focusing also out
drug algorithms you for already of methods creation. combination of and IO I/O many know, a development response As response wealth in drug and there's prediction
very tumor we be important IO certain to more have in either Our make advantage this and them, a incorporate deepen We our IO in and many tumors. XXX, believe will will They'll TMB combination improve them, to meaning review work TMB even or areas: with antibody agents, synergistically as team especially potential capabilities strategic high stronger. XXX drug mutation high in in development will -- already therapies and significant and show this that our We platform intractable agents. especially certain burden of as using high, they X these. they'll think -- reason may conjugate sensitivity marked challenging that the cancers have those long-term
trials of from a through had done X did fit in clinical Turning Professor importance. testing we drug higher the that of trial this XX,XXX Parker's significantly and a success Parker Jason colleagues his biomarkers. University attention Dr. multiyear covariant that that XXXX the think XXXX inclusion XXX his Dr. that and stages. of to is of to XXx status the showed in solid X trajectories the Actually, were recent use reviewed to signature; drug study But team biomarker models biomarker they describe improved Toronto, my clinical than he trials tumors use the over programs, from biomarker-based by is out not they Markov those real of across that rates concluded
Markov was had the So on of models biomarkers of and solid likelihood drug outperform Xx diseases a lung biomarkers the with and analysis. in tumors. Xx biomarkers, biomarker average highly all all it melanoma major And cell models and Markov by no related approval an increase that cancer, with with X across non-small factor. Xx, models, a cancer, Markov even XXx, by ratios now hazard the reveal are respectively, driven breast exploratory
is our we indications So in his biomarker team's that success this development oncology first first is the exploratory with multiple further drugs This review conclusion, had improve many rates biomarker-derived development therapies billion signatures a drug now $XXX the properly RADR process. -- long-term growing industry in the potential solutions and addressing and therapies oncology drug a combination the We unique discovery. has global market, has precision interest it innovate development witnessed that labs clinical clinical all, independently utilizing And aggressive importantly, risk the important cost. statistical solutions firsthand drug precision and just thing our future This drug goal believe of well, and in that partnerships and value. will evidence and the drive trials. of long place drug we and the before We've signatures reduce cancer the encourages that in of development increased cancer candidates systematic for clear one in committed validated our greater in and oncology of will biomarkers world's kind remain one new process. pave the our and investor of our across development. done road significantly already. is success very This they showed for appetite appear on clearly of adoption oncology. We trial of these ultimately, to but biomarkers very there also AI platform platform know in to way are building kinds pave a early we're largest hallmark that to the of We biomarker-based rates signatures solutions road of supports believe us achieving to -- in this
ADC with that is data next will uncovering XX IO both internally from our development. points, to therapeutic rare collaborators. to over We and on potential will AI and get opportunities add focus opportunities add valuable pivotal Our goal new several cancers, billion also cancers deepen believe and year platform in data aid and our additional be in third-party blood that
getting Now, drug into candidates. our
in brain we During preclinical cancer reported pancreatic quarter, cancer. GBM, the for LP-XXX and positive data glioblastoma multiforme
we and development in We next about year phase be for talk cancers nervous toward prostate Phase area of for LP-XXX in blood LP II out as clinical quarter. have later, significant And the potentially non-small exciting XXX focus. -- we assessment LP-XXX we'll castration-resistant also prepared cell cancers also smokers of XXX cancer advanced program and a cancer. We in LP-XXX that metastatic lung coming a of further data will next sorry, later trial some in in other XXXX began our this
cancer. pancreatic drug a Now We're XXX encouraging result designation. in orphan granted and GBM first, of the as results in
as several about, us designation reduced here exclusivity trials quarter. for many Two for assistance very both in the waiver benefits, and years, fees burden eligibility our reduce of annual expedited qualified clinical manner. of accomplished U.S., development areas Now increased product market credits past early that look fees, clinical gives receiving hopefully, because protection. all registration in massively for done X product well give this of important validation, you marketing they important review, These and for us investors they know call orphan commercial which application we've an in the are and drug tax should as positive as in
important orphan our validation We continue designation to also of approach. an but AI-driven at novel as look milestone
potentially we're provides unique increased abstract Bhatia, Officer, an the Virtual and a and of at He's we presentation models, showed cancers and Cancer Astrosoft potentially at in over also study Marvin very pancreatic and And data synthetically work that Institute as cancer also Center, a Kanchana the The that This DNA or show care cancer. road mechanism cancers about and that's first-in-class efficacy particularly existing talk observe also of an but LP-XXX Conference the pancreatic harbored Greenberg mice was significant kind did was efficacy some unique, cancers will the of that about care showed Fox continuing were showed of later. area prioritizing that NCI-funded Igor with deficiency. pancreatic lethal outcomes. solutions LP-XXX pancreatic agent it cancers repair development action. a in Pancreatic damage best-in-class submitted established efficacy only where that can the is we in in Dr. scientist. also physician Scientific Cancer map designed AACR resistant improvement standard accepted to the Kishor about We multiple and abstract XXX with pancreatic us not further a develop that additional of that standard We in that for had for good released because potentially also Chief drugs. of co-leader it effect Chase our in
very various future importantly, and developing CRISPR also does directly predicted XXX. PTGRX biomarker-driven no really we that look just to gene biomarker of the in actually can activity the had scenario charts. activity. It's there, a and exploit once saw approach not through the we again, is mechanism showed, if really antitumor we cancer biomarker and was saw black-and-white only We almost to pancreatic editing, activity PTGRX RADR this in And beyond very that trials. believe importantly, we but we tumors selecting take exquisite where link at This you the the using
Dr. pancreatic finish We'll plan XXX XX, we very then trials hosting virtual once LP-XXX studies. on event announce the next this We other treatment Kishor we'll for on I we've as and year cancer you, design, application. -- Chase later in also KOLs tell clinical that are of in November Fox Phase details pancreatic the in be this will We in World pleased in the Bath cancer Cancer -- with week. those IND with in and announce the landscape. Bhatia event I'm collaboration initiated will Pancreatic a Dr. on the Astrosoft or KOL And for IND-enabling and first-in-human now Day. discussions guide Eager to studies inform human
and what very statistically meaningful Kennedy way. University. done focus feel in models GBM, glioblastoma. a drug This intractable candidate. with LP-XXX cancer study another reported animal Johns was indication a in And to we able also expected against multi-billion-dollar this importantly We is survival and the clinical significantly Krieger global this results was Hopkins application of and are guide to study of improve
Kennedy treatment important next look is we and regardless its think Now enzyme our that to very in we've phase, silico MGMT, of the about cancer drug, gives in is work potentially potential the we a a that with as can the which that actually in observation only that of we've of MGMT And on in phase into next much-needed ability at LP-XXX GBMs overexpress believe TMZ. significant is important of status Hopkins that Krieger, can repair not it in this in the year. this to and effective that that now be GBM to you is an glioblastoma, GBMs. at but about a next status, taking mice, information looked we Johns expand XX% respond DNA treatment temzolimide, observation. has be have one an a that lab, to effective especially the alternative that care of proven we and to in standard We plan which provide seen humans But gives
therapy options. a a and drug that These overexpressing to generally are are that needs new population major MGMT is choice. this patients So the new TMZ unresponsive
a regardless an status this elsewhere. exploited and addressing of important towards development gap, is be in an pathway So critical that would efficacy agent we be can believe advancement molecular MGMT GBM of with
in LP-XXX current actually actually, silico work analysis regardless shows the in of MGMT many cancers. shows it But enough, increased status. actually Our should interestingly that sensitivity
studies the to few also additional second we ADC specific have quarter plan of launching and in program and Now, for XXXX to ADC designations. we a expect our program for data during in QX, the
that So to agent a right healthy the and targeted science unlike very a conventional damage side ADCs the cancer the specific even some the chemotherapy a cytotoxic toxic of agents that chemotherapy is linkers. target effects, deliver therapies have molecular can medicines a molecule cells and are the or or to connecting or or targeted through little bit cell ADC can
oncology year reworking program last an were of where believe been high cancer, clear our And market potency a of opportunity and relevant X the this deals specificity year of perfecting take on And of we've we it's Now more the of can ADCs molecule selected. be ADC more some platform represents a huge advantage becoming X only critical this. area We is largest assets. licensing superior part therapeutic our continue AI will believe that of as we the that and we've antibodies the our armamentarium it's the to against an powerful. out and ADC
entered now we've faster of patients a protocol. cancer candidate; one It's the that recruitment Lens. a our collaboration on meet care with Deep into company LP-XXX strategic that's Turning to thing, enabled health digital best-suited
trial a using where AI find their we're So clinical using to patients. we're to AI the to But actually create technology, we're the leveraging then AI drug. basically end-to-end basically develop unique solution Viper,
criteria to lung case, of come understand thousands smokers and cell the is technology non-small allow and patients. from So trading or are through the chemo-naive that us right like to and that TKI. our with to match In health relapsing cancer able medical never their records records thousands
chain then issues some equipment experienced COVID-XX, then global by equipment. into sourcing and initially backup and eventually have seeking some availability and we sourcing Now supply shipment caused
very a Phase delayed are but focused we have in launch II we never in patients. this are finalizing population. we're cell this a XX-patient quarter, for believe population, in and list clear on So early the other the future, non-small focused in lung manufacturing, protocol our planning trials we cancer a clinical no trial meaning near later There and the QX U.S. with unique selection smoker in to the
fairly planning on at select now each smokers to XX never sites in quickly. the and U.S., about can we're enrolling sites, believe we, and So X patients X of we these
collaborators. to scientific on manner very operations not on patient cost-efficient new with find platform side share network and to the simple it AI allows suggest will us us us outcomes transferable industry. discoveries, existing internal importantly, and it more to We the adds allows us secure, and do Viper time to a a time with treatment. scientific much their leaders terms our so reduce AI It companies more drug of with reduce in with to in to Our the proactively Code platform patients year turn allows such to different environment but exciting computational in allows takes external the like-minded and this appropriate collaborations manage allows really as always use cost. our internally the and, are our cost. or for match more But research and development side, more platform Code We'll line data think to the RADR leading our that our of patients and in already discoveries and their efficiencies to sharing areas. environment, Ocean, Ocean ease next code One that companies can externally in and us
powers collaborators we have or faster as our think with only for research but more institutions. we collaborative at distributed discoveries, this major So teams internally our not platform also
needed and of research committed Lantern, milestones this we awareness as and coverage our across we pleased Lantern initiated have. the positive also Bank data I'm remain H.C. we development. upcoming therapy only we community, progress investment that this the again well, announced the committed. growing within by and that cancer number change quarter, quarter to Investment evidenced associated not of advancements the the on that with remain are Wainwright also with We've risk cost has especially and excited believe exciting these of clinically some number to but types advancements As of that are measures, any very and
we'll about; a and a of sure, XXX ADC in we'll program, also in coming GBM number progress talk our months. bladder pancreatic IND-enabling the for studies indications, have our which, and in of in program; in the We progress for ATRT results including lot have
of our share. overview we also, provide Margrave, to So ask to David of we our financial an to continued I'll CFO, lot third data But results. have good discipline. show a financial have quarter David? And
